Drug intelligence / Profile preview

SCTV01E-1

Development stage: Phase 2
Lead developer: Sinocelltech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SCTV01E-1 is a recombinant protein-based, multivalent COVID-19 vaccine candidate developed to provide broad protection against SARS-CoV-2 variants. It is closely related to SCTV01E, which is a tetravalent vaccine containing trimeric spike proteins from the Alpha, Beta, Delta, and Omicron BA.1 variants of SARS-CoV-2 and formulated with a squalene-based oil-in-water adjuvant (SCT-VA02B). The mechanism of action involves inhibition of the SARS-CoV-2 spike glycoprotein by inducing neutralizing antibodies that block viral entry into host cells. Clinical studies are evaluating its safety and immunogenicity in adults both previously vaccinated and unvaccinated for COVID-19[5][6].

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SCTV01E-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCTV01E-1.

Explore the full profile